Journal article
Fluticasone Furoate–Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial
Abstract
BACKGROUND: The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β2-agonist vilanterol (VI) is under development for the treatment of asthma and chronic obstructive pulmonary disease.
OBJECTIVE: To compare the efficacy and safety of FF-VI and FF in patients (≥ 12 years old) with persistent asthma.
Authors
Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L
Journal
The Journal of Allergy and Clinical Immunology In Practice, Vol. 2, No. 5, pp. 553–561
Publisher
Elsevier
Publication Date
September 2014
DOI
10.1016/j.jaip.2014.02.010
ISSN
2213-2198